Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06647498 · ClinicalTrials.gov registry record · Phase 2

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

A Phase 2 study of Dementia and Alzheimers Disease, sponsored by Washington University School of Medicine.

Recruiting
Registry status
Phase 2
Development phase
280
Enrollment target
20
Study locations

NCT06647498: Recruiting Phase 2 study of Dementia and Alzheimers Disease, sponsored by Washington University School of Medicine.

NCT06647498 is a Phase 2 study of Dementia and Alzheimers Disease that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 280 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06647498, a Phase 2 study of Dementia and Alzheimers Disease, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
Phase 2
Development phase
280 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.

Primary Outcome

CL calculated using \[11C\] PiB PET non-partial volume corrected (regional spread function) standardized uptake value ratio cortical composite (PiB PET SUVR) is the primary outcome and change from baseline at 2 years is the primary endpoint.

Conditions Studied

Dementia Alzheimers Disease Alzheimers Disease, Familial

Interventions

  • DRUG Remternetug
  • DRUG Matching Placebo (Remternetug)

Study Locations (20)

Other

  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI - Ciudad Autonoma de Buenos Aire
  • CHU de Quebec - Hôpital de l' Enfant Jésus - Québec
  • Grupo de Neurociencias Sede de la Universidad de Antioquia - Medellín

Alabama

  • University of Alabama in Birmingham - Birmingham

California

  • University of California San Diego Medical Center - La Jolla

Connecticut

  • Yale University School of Medicine - New Haven

Georgia

  • Emory University - Atlanta

Illinois

  • Advocate Lutheran General Hospital - Park Ridge

Indiana

  • Indiana University School of Medicine - Indianapolis

Missouri

  • Washington University in St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2024-11-22
Est. Completion 2034-08
Phase Phase 2
Washington University School of Medicine

1,502 total trials

What NCT06647498 shows while recruiting

NCT06647498 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Dementia appearing as the primary indexed condition, and to 2 interventions - of which Remternetug is the first listed.

NCT06647498 names 20 study sites across 18 states, led by Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06647498 about?

NCT06647498 is a clinical study titled "A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation". The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomar...

What is the current status of trial NCT06647498?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2024-11-22. Estimated completion is 2034-08.

What conditions does trial NCT06647498 study?

This clinical trial studies the following conditions: Dementia, Alzheimers Disease, Alzheimers Disease, Familial.

What interventions are being tested in trial NCT06647498?

The interventions under investigation include: Remternetug (DRUG), Matching Placebo (Remternetug) (DRUG).

Who is sponsoring clinical trial NCT06647498?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06647498 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dementia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06647498's enrollment target sits among peer trials

280 75th of 199 higher than 124 of 199 other Dementia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04084730 · 280 participants · Phase 2

    Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

  • NCT04518657 · 280 participants · NA

    Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis

  • NCT04634916 · 280 participants · NA

    Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

  • NCT04829617 · 280 participants · NA

    Promoting Well-being and Health in Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06647498

Source: ClinicalTrials.gov NCT06647498, the US trial registry maintained by the National Library of Medicine. NCT06647498 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.